Search the RE article base
Contact Information
Twitter
My TweetsUseful Web Sites
Tag Archives: march-in
Making Bayh-Dole March-in and Government License Work
There’s a lot of stirrings about using Bayh-Dole’s march-in procedure to address the high price of drugs in the United States. Under march-in, a federal agency has the right to require a federal contractor (or anyone who is an assignee … Continue reading
Posted in Bayh-Dole
Tagged Bayh-Dole, march-in, practice and have practiced
Comments Off on Making Bayh-Dole March-in and Government License Work
Unenforced, Bayh-Dole enables a federal offer to look the other way on price-gouging
The government’s failure to use its government license to practice and have practiced (=make, use, and sell) puts undue pressure on march-in to address nonuse and unreasonable use of inventions arising in work receiving federal support. NIST wants to gut … Continue reading
Posted in Bayh-Dole, high priced medicines, History, Vannever Bush
Tagged Bayh-Dole, government license, march-in, monopoly pricing, NIST
Comments Off on Unenforced, Bayh-Dole enables a federal offer to look the other way on price-gouging
proto Bayh-Dole march-in, c. 1976
Bayh-Dole was the banana that finally stuck on wall, but Norman Latker had tried any number of schemes to circumvent federal policy requiring default open access to the inventions arising in work for which the federal government provided funding. People … Continue reading
Reflections on Shill Reflections on Bayh-Dole, 7: Grubbers, innovation, and march-in
Reflections on Bayh-Dole by “industry leaders”–who are, apparently, mostly shills out shilling for (and to) the pharmaceutical industry. Good shilling earns shillings, so it is a viable career choice. We use these shills reflecting on Bayh-Dole to also reflect on … Continue reading
The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir
Sally Pipes has published an op/ed piece at the Wall Street Journal on Bayh-Dole and Gilead, “The Remdesivir Patent Isn’t State Property.” There is so much going on with Pipes’s work. We should take a closer look. First, the title … Continue reading
Posted in Bayh-Dole, high priced medicines, Policy
Tagged Bayh-Dole, ludicrous, march-in, remdesivir
Comments Off on The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir
Defense Contracting, Bayh-Dole Fantasies, and Workarounds–3
We have been working through a DoD guide for contracting officers in navigating IP rights–Bayh-Dole and data rights. The data rights are a whole nother saga, so we are leaving them alone for now. Here in summary form are the … Continue reading
Posted in Bayh-Dole
Tagged Bayh-Dole, manufactured substantially, march-in, trade secret
Comments Off on Defense Contracting, Bayh-Dole Fantasies, and Workarounds–3
Bayh-Dole Nutshell 1: Use it or lose it
If you don’t achieve practical application in a reasonable time, you lose the right to enforce your patent. Bayh-Dole’s fundamental policy is that the patent system must be used to promote the utilization of inventions arising from federally supported research … Continue reading
Four things not to know about Bayh-Dole
PhRMA, a pharma front group, published a discussion of Bayh-Dole, “IP Explained: Four things to know about the Bayh-Dole Act.” Short form. This is nonsense. I’ll show you briefly. Thanks in large part to strong intellectual property protections – including … Continue reading
IP Watchdog Misses the Mark on March-In Rights
IPWatchdog, a blog site, published on April 22, 2020 an article by Joseph Allen arguing that the Washington Post got Bayh-Dole’s march-in provision all wrong. But Allen has got it wrong. Let’s be clear, then, about Bayh-Dole and march-in. Even … Continue reading
Posted in Bayh-Dole
Tagged Bayh-Dole, march-in, reasonable terms
Comments Off on IP Watchdog Misses the Mark on March-In Rights
International Response to Bayh-Dole
You may have heard that Bayh-Dole is the most perfect law to stimulate technological innovation and translate publicly supported research into public benefit by passing inventions through the hands of speculative investors to be made into commercial products, using patents … Continue reading